T. Rowe Price Investment Management
AKRO

T. Rowe Price Investment Management’s Akero Therapeutics AKRO Stock Holding History

T. Rowe Price Investment Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-670,048
Closed -$18.6M – 658
2024
Q4 		$18.6M Sell
670,048
-630,048
-48% -$19.1M 0.01% 521
2024
Q3 		$37.3M Sell
1,300,096
-467,147
-26% -$12.2M 0.02% 449
2024
Q2 		$41.5M Buy
1,767,243
+665,194
+60% +$14.2M 0.03% 415
2024
Q1 		$27.8M Buy
+1,102,049
New +$26.5M 0.02% 473

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

T. Rowe Price Investment Management's AKRO Position: Q1 2025 in Review

T. Rowe Price Investment Management sold out of Akero Therapeutics (AKRO) in Q1 2025, closing a stake of 670,048 shares — an estimated $18.6M sold.

T. Rowe Price Investment Management first reported a position in AKRO in Q1 2024 and held it in 4 quarters. The position peaked at $41.5M in Q2 2024. 240 funds tracked by Wall St. Rank hold AKRO as of Q1 2025.

  • T. Rowe Price Investment Management reported no remaining Akero Therapeutics position as of Q1 2025 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 670,048 Akero Therapeutics shares in Q1 2025, an estimated $18.6M.
  • T. Rowe Price Investment Management first reported a position in Akero Therapeutics in Q1 2024 and held it in 4 quarters.
  • T. Rowe Price Investment Management's Akero Therapeutics position peaked at $41.5M in Q2 2024.
  • 240 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2025.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2025, filed 14 May 2025.